Literature DB >> 1372533

Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice.

N Peat1, S J Gendler, N Lalani, T Duhig, J Taylor-Papadimitriou.   

Abstract

The human MUC1 gene codes for the core protein of a mucin which is expressed by glandular epithelia and the carcinomas which develop from these tissues. The core protein is aberrantly glycosylated in cancers, and some antibodies show specificity in their reactions with the cancer-associated mucin, which also contains epitopes recognized by T-cells from breast and pancreatic cancer patients. For evaluating the potential use of mucin-reactive antibodies and mucin-based immunogens in cancer patients, a mouse model, expressing the MUC1 gene product PEM (polymorphic epithelial mucin) as a self antigen, would be extremely useful. To this end, we have developed transgenic mouse strains expressing the human MUC1 gene product in a tissue-specific manner. The TG4 mouse strain was established using a 40-kilobase fragment containing 4.5 kilobases of 5' and 27 kilobases of 3' flanking sequence. The TG18 strain was developed using a 10.6-kilobase SacII fragment from the 40-kilobase fragment; this fragment contained 1.6 kilobases of 5' sequence and 1.9 kilobases of 3' flanking sequence. Both strains showed tissue specificity of expression of the MUC1 gene, which was very similar to the profile of expression seen in human tissues. The antibody SM-3 is directed to a core protein epitope, which is selectively exposed in breast cancers and which shows a more restricted distribution on normal human tissues. It was established that the distribution of the SM-3 epitope of PEM in the tissues of the transgenic mice is similar to that seen in humans. The transgenic mouse strains described here should form the basis for the development of a preclinical model for the evaluation of PEM-based antigens and of antibodies directed to PEM in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372533

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration.

Authors:  Isabel Correa; Tim Plunkett; Anda Vlad; Arron Mungul; Jessica Candelora-Kettel; Joy M Burchell; Joyce Taylor-Papadimitriou; Olivera J Finn
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

2.  O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.

Authors:  D Stepensky; E Tzehoval; E Vadai; L Eisenbach
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

3.  Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.

Authors:  M Smith; J M Burchell; R Graham; E P Cohen; J Taylor-Papadimitriou
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

4.  MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices.

Authors:  M J Hudson; G W Stamp; M A Hollingsworth; M Pignatelli; E N Lalani
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 5.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 6.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

7.  Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes.

Authors:  Adam M Farkas; Douglas M Marvel; Olivera J Finn
Journal:  J Immunol       Date:  2013-02-18       Impact factor: 5.422

8.  MUC1 expression in Sjogren's syndrome, KCS, and control subjects.

Authors:  Barbary Caffery; Miriam L Heynen; Elizabeth Joyce; Lyndon Jones; Robert Ritter; Michelle Senchyna
Journal:  Mol Vis       Date:  2010-08-24       Impact factor: 2.367

Review 9.  The gastrointestinal mucus system in health and disease.

Authors:  Malin E V Johansson; Henrik Sjövall; Gunnar C Hansson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-12       Impact factor: 46.802

10.  Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.

Authors:  Yefei Rong; Dayong Jin; Wenchuan Wu; Wenhui Lou; Danshong Wang; Tiantao Kuang; Xiaoling Ni; Xinyu Qin
Journal:  BMC Cancer       Date:  2009-06-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.